If you have worked in pharma, HEOR, or life sciences AI over the past two years, you have heard the term knowledge graph used to describe everything from a company's internal database to a sophisticated AI reasoning engine. You may have also encountered related terms, including context graph, semantic layer, ontology, and knowledge base, used interchangeably in ways that suggest they mean the same thing. They do not. The distinctions matter practically, not just technically, because the architecture choice determines whether your AI outputs are traceable, whether your evidence is hallucination-free, and whether your organisation builds an institutional intelligence asset or a collection of isolated query sessions.
This guide cuts through the jargon and explains what an enterprise knowledge graph actually is, how it works in life sciences specifically, and why the leading pharma organisations are building them as the foundation of their AI intelligence infrastructure. Pienomial's Knolens platform is built on an enterprise context graph purpose-built for life sciences, and this post explains the architecture and its value.[9]
1. Start with the Problem: The Knowledge Challenge in Life Sciences
Life sciences organisations are knowledge-intensive in a specific and demanding way. Clinical trial results, regulatory decisions, HTA outcomes, scientific publications, competitive intelligence, and internal analyses: all of this information needs to be organised, connected, and queried in ways that support decisions with real consequences.[4]
The traditional solutions each have a fundamental limitation. Relational databases organise data in tables. They answer questions like 'show me all trials for compound X.' They cannot traverse relationships between entities in a way that supports complex clinical intelligence queries. Document repositories store unstructured content that can be searched by keyword but cannot be reasoned over. The evidence that pembrolizumab was approved for first-line NSCLC with PD-L1 TPS greater than or equal to 50% is in hundreds of documents, but no document repository can answer 'which other compounds target the same pathway and have been approved in the same indication with similar endpoint criteria.' Spreadsheets and slide databases are flexible but are not connected, not queryable at scale, and not maintained continuously.
The enterprise knowledge graph solves the knowledge organisation problem by storing information as a network of connected facts rather than as rows and columns or isolated documents. This architectural difference is what enables the complex, multi-step reasoning that life sciences intelligence requires.[5]
2. The Plain-English Definition: What a Knowledge Graph Is
A knowledge graph is a database that stores information as a network of connected facts. In life sciences terms: nodes represent things, including compounds, diseases, genes, biomarkers, clinical trials, regulatory decisions, patient populations, and HTA outcomes. Edges represent the connections between those things, including typed, directed relationships that encode specific facts.[6]
A stored relationship in a pharma knowledge graph reads: Pembrolizumab is approved for first-line NSCLC with PD-L1 TPS greater than or equal to 50%, based on FDA approval record dated October 2016. Every relationship carries its provenance: the specific source document, the date, and the location within the document from which the relationship was extracted and validated.
The result is a web of interconnected facts that can be queried by traversing the network of relationships. A query for pembrolizumab approvals in NSCLC does not retrieve a document about pembrolizumab. It traverses the compound-approval-indication-population-endpoint relationship path and returns the specific sourced answer. Expanding that query to include all PD-1 inhibitors approved in the same indication, comparing their approved endpoint criteria, and identifying which ones had head-to-head data against each other is a multi-hop traversal that no database query or document search can execute, but that an enterprise knowledge graph handles natively.[7]
3. How is a Knowledge Graph Differs from a Relational Database
The comparison to a relational database clarifies the architectural difference. A relational database stores data in tables with a predefined schema: columns have fixed types, rows represent individual records, and relationships between tables are represented as foreign key joins. The schema must be defined before data is entered and modified carefully as requirements change.
In a relational database, queries use SQL to retrieve and join data: efficient for structured, well-defined data with consistent schema, but poor at representing heterogeneous relationships or answering questions that require traversing multiple entity types. A query asking which compounds that inhibit a specific kinase target have been tested in combination with anti-PD-1 agents in patients with prior platinum chemotherapy, where the trial enrolled patients with ECOG performance status 0 to 1, would require five or more table joins in a relational model and is difficult to express efficiently in SQL.
A knowledge graph stores this same query as a relationship traversal: compound, target, combination, indication, prior therapy, and performance status are all entities connected by typed relationships. The query traverses the network and returns exactly the compounds that meet all five criteria, with source attribution for every relationship traversed.[3]
4. How a Knowledge Graph Differs from a Vector Database Used in RAG
A vector database converts text into numerical vector representations and retrieves documents by semantic similarity. When a query arrives, it is converted to a vector and the database returns the documents with the most similar vector representations. This is the architecture underlying most RAG systems.[7]
The critical limitation for life sciences: similarity is not the same as accuracy. A vector database may return a document about nivolumab PFS in second-line NSCLC in response to a query about pembrolizumab PFS in first-line NSCLC because both involve I-O PFS in NSCLC and the vectors are similar. The clinical facts are different. In a competitive intelligence context, this retrieval error produces an incorrect competitive claim that was attributed to a retrieved document and appears credible.
A knowledge graph stores facts explicitly as verified entity-relationship triples, not as probabilistic vector representations. The query for pembrolizumab PFS in first-line NSCLC traverses the specific entity-relationship path and returns the specific sourced answer. There is no similarity-based retrieval that could return a related-but-wrong fact. A 2025 Gartner finding confirmed that organisations using structured knowledge layers with LLMs reduced AI-generated error rates by more than 60% compared to standard RAG systems. [8] This is the architectural reason why leading pharma organisations are moving beyond RAG to enterprise knowledge graph platform infrastructure for their most consequential AI use cases.
5. What makes Enterprise Knowledge Graphs different?
A research-grade or prototype knowledge graph may contain thousands of entities and relationships for a specific domain. An enterprise knowledge graph operates at a fundamentally different scale and adds five capabilities.[4]
Scale: Enterprise life sciences knowledge graphs contain millions of entities and hundreds of millions of relationships, built from thousands of source documents spanning clinical, regulatory, commercial, and scientific domains. Novartis has been building and scaling a knowledge graph that links genes, diseases, and compounds from PubMed text mining and internal biological data for over a decade, with the graph now functioning as a central query infrastructure for drug discovery research. [1][2]
Governance: Update workflows with validation and approval before new relationships enter the graph. Access controls at the entity and relationship level. Complete audit trail for every change to graph content with timestamp and actor identity. Version control with rollback capability. These governance properties are what make an enterprise knowledge graph deployable in GxP-regulated environments.
Domain ontologies: Validated vocabularies that encode the semantic relationships specific to life sciences: MeSH for disease and compound classification, ICD for indication coding, ATC for drug classification, MedDRA for adverse event coding, and gene ontologies for biological pathway classification. Domain ontologies ensure that NSCLC, non-small cell lung cancer, and lung adenocarcinoma are understood as related concepts and not treated as different strings.
Integration: Connections to proprietary enterprise data: internal clinical databases, regulatory submission history, commercial data, and competitive intelligence repositories. The enterprise knowledge graph is not just a repository of public information. It is the connective infrastructure that links proprietary enterprise knowledge to published evidence.[5]
Persistence and institutional memory: The enterprise knowledge graph accumulates knowledge continuously. Every analysis conducted, every source ingested, and every relationship validated becomes part of the permanent organisational knowledge base. Unlike a query session that produces no residue in the system, the knowledge graph grows more valuable with every interaction.
6. How Knowledge Graphs Are Built: The Extraction and Validation Process
Building an enterprise knowledge graph involves three main processes. Understanding these processes helps demystify the technology for non-technical pharma decision-makers.[3]
Entity and relationship extraction: Source documents including clinical publications, regulatory filings, HTA decisions, and patent applications are processed to identify entities and the relationships between them. Text mining extracts facts such as 'pembrolizumab demonstrated OS benefit in first-line NSCLC in KEYNOTE-024' from source text. Structured parsing processes databases and regulatory filings with defined formats. The output is a set of candidate entity-relationship triples with their source locations.
Entity resolution: The same entity may appear with different names across sources: pembrolizumab, MK-3475, Keytruda, and anti-PD-1 number 3 are all names for the same compound. Entity resolution matches these references to the same canonical entity node in the graph. Domain ontologies are the primary tool for entity resolution in life sciences, providing standardised identifiers for compounds, diseases, genes, and other entity types.
Relationship validation: Extracted relationships are validated for accuracy before being ingested into the enterprise graph. Validation may be automated, by cross-referencing extracted relationships against structured databases such as ClinicalTrials.gov for trial data or FDA drug databases for approval data, or human-reviewed for novel or complex relationship claims. Only validated, sourced relationships are stored. This validation step is what distinguishes a governed enterprise knowledge graph from a GraphRAG graph that may contain LLM-hallucinated relationships.[8]
At enterprise scale, this three-step process must run across thousands of source documents simultaneously, maintain consistency across millions of entity-relationship pairs, and update continuously as new evidence is published, which is precisely why a purpose-built life sciences knowledge graph platform delivers what no general-purpose tool or manual curation process can sustain over time. [4]
7. Five High-Value Use Cases in Life Sciences
The value of an enterprise knowledge graph in life sciences becomes concrete through its use cases.[4]
Use Case 1, Clinical trial landscape intelligence: Query all Phase III trials in a specific indication with defined endpoint, patient population, and comparator criteria. Understand the competitive evidence landscape before Phase III protocol lock, including which endpoints have been accepted by regulators in analogous indications and which patient population definitions have been used.
Use Case 2, Competitive intelligence: Traverse the compound-programme-regulatory-commercial relationship network for a competitor. Identify pipeline patterns, endpoint strategy, regulatory precedent, and market access positioning across indications and geographies.
Use Case 3, HEOR evidence synthesis: Retrieve all clinical evidence for a specific PICOTS question with source attribution at the sentence level. Generate structured evidence tables for HTA dossier preparation with full traceability from evidence table entry to source publication location.[6]
Use Case 4, Regulatory precedent analysis: Query the regulatory decision network for analogous submissions in the same indication and mechanism class. Identify the evidence standards that supported approval, the endpoints that were accepted, the patient populations that were included, and the label language that resulted.
Use Case 5, Market access intelligence: Connect HTA decisions to clinical evidence, payer landscape, and pricing data across markets. Identify the evidence requirements that produced favourable versus unfavourable reimbursement outcomes for analogous products, enabling proactive evidence planning.[9]
8. How to Evaluate an Enterprise Knowledge Graph for Life Sciences
When evaluating an enterprise knowledge graph for a life sciences deployment, five criteria distinguish a production-grade platform from a research prototype.[8]
Criterion 1, Domain ontology quality: Does the knowledge graph use validated clinical ontologies including MeSH, ICD, ATC, and MedDRA? A graph built on proprietary vocabularies without validated clinical ontologies will produce entity resolution errors and miss semantic relationships that domain ontologies encode. Ask: can the graph correctly resolve that NSCLC and lung adenocarcinoma are related? That pembrolizumab and MK-3475 are the same compound?
Criterion 2, Source provenance at the relationship level: Is every relationship in the graph linked to a specific source document with author, publication date, and specific location? Document-level provenance is insufficient for HTA and regulatory use. Every claim must be traceable to a specific sentence or data table.[5]
Criterion 3, Update frequency and mechanism: How quickly does new evidence, including newly published clinical trials, new regulatory decisions, and new HTA outcomes, enter the graph? Is the update process automated and continuous, or manual and periodic? For competitive intelligence and HTA intelligence use cases, update frequency directly determines the strategic lead time the platform provides.
Criterion 4, Multi-hop query capability for life sciences: Can the graph answer multi-hop clinical intelligence questions of the type life sciences teams actually ask? Test with a specific example from your use case before selecting a platform.[7]
Criterion 5, Deployment options: Can the graph be deployed entirely within the organisation's private infrastructure with no external API dependency? Is the query engine and output layer deployable on-premise? Is the system LLM-agnostic, allowing privately hosted models to be used for output generation?
9. The Enterprise Knowledge Graph as Institutional Memory
The most underappreciated value of an enterprise knowledge graph for pharma organisations is institutional memory. Every time an analyst conducts a clinical trial landscape analysis, every time a HEOR team builds an evidence base for an HTA dossier, and every time a CI team synthesises competitive intelligence for a portfolio review, structured knowledge is generated that has value beyond the immediate output.
In a traditional workflow, this knowledge is embedded in documents: PowerPoint presentations, Word reports, Excel workbooks. It is not queryable, not linkable to future work, and not available to analysts who were not part of the original project. When the analyst who built the landscape moves to another role, the institutional knowledge they carried moves with them.[1]
An enterprise knowledge graph preserves institutional knowledge structurally. Every validated relationship added to the graph as part of an analysis is available to every future analyst who queries the same entity types. The knowledge base compounds in value with each project, each source ingested, and each relationship validated. This compounding is the long-term value driver that distinguishes a knowledge graph investment from a query tool investment, and it is the reason why organisations that commit to building their enterprise knowledge layer now are creating a structural intelligence advantage that grows larger over time.[9]
Conclusion
An enterprise knowledge graph is not a more sophisticated database or a smarter search engine. It is a fundamentally different way of organising and querying the knowledge that drives life sciences decision-making. For pharma, HEOR, and clinical teams that need to answer complex, multi-hop questions with source-attributed, hallucination-free outputs, a knowledge graph is the correct architectural foundation for AI deployment.
Pienomial's Knolens platform is built on an enterprise knowledge graph and enterprise context graph AI architecture, purpose-built for life sciences, with clinical domain ontologies, relationship-level provenance, and full private deployment capability. The teams building this infrastructure now are creating the intelligence foundation that will define their competitive and regulatory advantage for the next decade. [9] CTA: Book a Knowledge Graph Architecture Demo or Download the Enterprise Knowledge Graph Buyer's Guide for Life Sciences.
